Is ALS a multistep process?

Similar documents
Mathematics and Physics of Cancer: Questions. Robijn Bruinsma, UCLA KITP Colloquium May 6, ) Cancer statistics and the multi-stage model.

Development of Carcinoma Pathways

HST.161 Molecular Biology and Genetics in Modern Medicine Fall 2007

Asingle inherited mutant gene may be enough to

Cancer and Oncogenes Bioscience in the 21 st Century. Linda Lowe-Krentz

Serrated Polyps and a Classification of Colorectal Cancer

Tumor suppressor genes D R. S H O S S E I N I - A S L

Colorectal adenocarcinoma leading cancer in developed countries In US, annual deaths due to colorectal adenocarcinoma 57,000.

Hereditary Non Polyposis Colorectal Cancer(HNPCC) From clinic to genetics

Cancer Genetics. What is Cancer? Cancer Classification. Medical Genetics. Uncontrolled growth of cells. Not all tumors are cancerous

Neoplasia 18 lecture 6. Dr Heyam Awad MD, FRCPath

Cancer and sornat ic evolution

Familial and Hereditary Colon Cancer

Colon Cancer and Hereditary Cancer Syndromes

Multistep nature of cancer development. Cancer genes

Cancer genetics

Cancer develops after somatic mutations overcome the multiple

Biochemistry of Carcinogenesis. Lecture # 35 Alexander N. Koval

TumorNext-Lynch. genetic testing for hereditary colorectal or uterine cancer

Colonic polyps and colon cancer. Andrew Macpherson Director of Gastroentology University of Bern

oncogenes-and- tumour-suppressor-genes)

Clonal evolution of human cancers

Colorectal Cancer - Working in Partnership. David Baty Genetics, Ninewells Hospital

Familial and Hereditary Colon Cancer

FACT SHEET 49. What is meant by a family history of bowel cancer? What is bowel cancer? What causes bowel cancer?

Multistep Carcinogenesis

A class of genes that normally suppress cell proliferation. p53 and Rb..ect. suppressor gene products can release cells. hyperproliferation.

Overview of the core ideas in cancer research

Mohammed El-Khateeb. Tumor Genetics. MGL-12 July 21 st 2013 台大農藝系遺傳學 Chapter 22 slide 1

Mr Chris Wakeman. General Surgeon University of Otago, Christchurch. 12:15-12:40 Management of Colorectal Cancer

Genetic testing all you need to know

Mohammed El-Khateeb. Tumor Genetics. MGL-12 May 13 th Chapter 22 slide 1 台大農藝系遺傳學

LESSON 3.2 WORKBOOK. How do normal cells become cancer cells? Workbook Lesson 3.2

AllinaHealthSystems 1

PROJECT TRICALS AN INTERNATIONAL COLLABORATION TO FIND EFFECTIVE TREATMENTS FOR AMYOTROPHIC LATERAL SCLEROSIS

Resource impact report: Molecular testing strategies for Lynch syndrome in people with colorectal cancer (DG27)

- A cancer is an uncontrolled, independent proliferation of robust, healthy cells.

- is a common disease - 1 person in 3 can expect to contract cancer at some stage in their life -1 person in 5 can expect to die from it

What All of Us Should Know About Cancer and Genetics

Cancer and Oncogenes Bioscience in the 21 st Century. Linda Lowe-Krentz October 11, 2013

Assessment of Universal Mismatch repair (MMR) or Microsatellite Instability (MSI) testing in colorectal cancers.

Genomics Up Close And Personal: What Are The Implications For Cancer Nursing? Candy Cooley Head of Education

609G: Concepts of Cancer Genetics and Treatments (3 credits)

Report OPERRA Workshop: Modelling of pathogenesis

CANCER Uncontrolled Cell Division

The Whys OAP Annual Meeting CCO Symposium September 20. Immunohistochemical Assessment Dr. Terence Colgan Mount Sinai Hospital, Toronto

Cancer arises from the mutation of a normal gene. A factor which brings about a mutation is called a mutagen.

Jay M. Baraban MD, PhD January 2007 GENES AND BEHAVIOR

Cancer. Questions about cancer. What is cancer? What causes unregulated cell growth? What regulates cell growth? What causes DNA damage?

Tumour Structure and Nomenclature. Paul Edwards. Department of Pathology and Cancer Research UK Cambridge Institute, University of Cambridge

Neoplasia part I. Dr. Mohsen Dashti. Clinical Medicine & Pathology nd Lecture

Sessile Serrated Polyps

Information for You and Your Family

Human Genetics 542 Winter 2018 Syllabus

Aberrant cell Growth. Younas Masih New Life College of Nursing Karachi. 3/4/2016 Younas Masih ( NLCON)

Human Genetics 542 Winter 2017 Syllabus

Beyond the APC era Alternative pathways to CRC. Jeremy R Jass McGill University

GENETIC TESTING: WHAT DOES IT REALLY TELL YOU? Lori L. Ballinger, MS, CGC Licensed Genetic Counselor University of New Mexico Cancer Center

Alcohol & Cancer: from prevention to the patient

COLORECTAL PATHWAY GROUP, MANCHESTER CANCER. Guidelines for the assessment of mismatch. Colorectal Cancer

Somatic evolutionary genomics: Mutations during development cause highly variable genetic mosaicism with risk of cancer and neurodegeneration

Invited Re vie W. Molecular genetics of ovarian carcinomas. Histology and Histo pathology

The Future of Cancer. Lawrence Tsui Global Risk Products Actuary Swiss Reinsurance Company Hong Kong. Session Number: WBR8

Present State of Gene Diagnosis and Future Prospects

Research Article Prevalence and Risk Factors of Gastric Adenoma and Gastric Cancer in Colorectal Cancer Patients

Introduction to Cancer Biology

colorectal cancer Colorectal cancer hereditary sporadic Familial 1/12/2018

The Genetics of Breast and Ovarian Cancer Prof. Piri L. Welcsh

Early Embryonic Development

James C. Fleet, PhD Professor Dept of Nutrition Science Purdue University

I have ovarian cancer

COLORECTAL PATHWAY GROUP, MANCHESTER CANCER. Guidelines for the assessment of mismatch. Colorectal Cancer

National Surgical Adjuvant Breast and Bowel Project (NSABP) Foundation Annual Progress Report: 2009 Formula Grant

Gene Therapy. Definition: A disease resulting from a defect in individual genes. > 6000 inherited diseases 1:200 Births

Landes Bioscience Not for distribution.

Chapter 9. Cells Grow and Reproduce

Molecular mechanisms of human carcinogenesis

GENETICS OF COLORECTAL CANCER: HEREDITARY ASPECTS By. Magnitude of the Problem. Magnitude of the Problem. Cardinal Features of Lynch Syndrome

Genetics of Pancreatic Cancer. October 6, If you experience technical difficulty during the presentation:

Cancer Cells. It would take another 20 years and a revolution in the techniques of biological research to answer these questions.

Guidelines for the assessment of mismatch repair (MMR) status in Colorectal Cancer

Genetics of Cancer Lecture 32 Cancer II. Prof. Bevin Engelward, MIT Biological Engineering Department

The lymphoma-associated NPM-ALK oncogene elicits a p16ink4a/prb-dependent tumor-suppressive pathway. Blood Jun 16;117(24):

DIAGNOSTICS ASSESSMENT PROGRAMME Diagnostics consultation document

CANCER. Inherited Cancer Syndromes. Affects 25% of US population. Kills 19% of US population (2nd largest killer after heart disease)

Analysis of Human DNA in Stool Samples as a Technique for Colorectal Cancer Screening

Colonic Polyp. Najmeh Aletaha. MD

Carcinogenesis. pathophysiology of altered cellular growth. Prof. Blagoi Marinov, MD, PhD Pathophysiology Department Medical University of Plovdiv

Joseph Misdraji, M.D. GI pathology Unit Massachusetts General Hospital

Hands-On Ten The BRCA1 Gene and Protein

Lecture 1: Carcinogenesis

CANCER = Malignant Tumor = Malignant Neoplasm

BASIC CONCEPTS OF CANCER: GENOMIC DETERMINATION

SNC2D BIOLOGY 3/24/2013. TISSUES, ORGANS & SYSTEMS OF L Cancer Cell Division Gone Wrong (P.32-34) Cancer Cell Division Gone Wrong

The silence of the genes: clinical applications of (colorectal) cancer epigenetics

Categories of Cancer. Categorized based on cellular typology

B Base excision repair, in MUTYH-associated polyposis and colorectal cancer, BRAF testing, for hereditary colorectal cancer, 696

Risk of Colorectal Cancer (CRC) Hereditary Syndromes in GI Cancer GENETIC MALPRACTICE

Results. NeuRA Motor dysfunction April 2016

Transcription:

Is ALS a multistep process? Neil Pearce, London School of Hygiene and Tropical Medicine Ammar Al-Chalabi, Institute of Psychiatry, King s College London Zoe Rutter-Locher, King s College London

Is ALS a multistep process? Multistage models Identification of stages Multistage model of ALS Implications for future research

Characteristics of cancer (Mostly) adult onset condition Even those born with a genetic susceptibility will usually not get the disease till old age, or not at all The same gene mutation can result in different phenotypes Starts in one region (probably with just one cell) and then spreads Once it occurs, then progression is usually relentless

Models of Carcinogenesis: The Armitage-Doll Model Cancer is established in stages (probably 5 or 6) These stages must occur in a particular sequence These stages are irreversible

1 2 3 4 5 6 Normal cell Cancer cell

u 1 u 6 1 u 2 2 u 3 3 u 4 4 5 6 u 5 Normal cell Cancer cell The chance of u 1 occurring by age t is u 1 t The chance if n-1 steps occurring by age t is u 1 u 2 u 3 u 4 u n-1 t n-1 The chance of the last step then occurring is u n

u 1 u 6 1 u 2 2 u 3 3 u 4 4 5 6 u 5 Normal cell Cancer cell The incidence at age t is approximately u 1 u 2 u 3 u 4 u 5 u 6 t n-1 If the steps have to be in a particular order then this becomes: u 1 u 2 u 3 u 4 u 5 u 6 t n-1 /(n-1)!

u 1 u 6 1 u 2 2 u 3 3 u 4 4 5 6 u 5 Normal cell Cancer cell Therefore at age t: I = u 1 u 2 u 3 u 4 u 5 u 6 t n-1 /(n-1)! Log(I) = (n-1)log(t) + c (where c is a constant) If we assume that this needs to happen in at least one cell line (out of many) then we multiply by the number of cell lines (approximately); The constant then changes, but the formula itself doesn t

u 1 u 6 1 u 2 2 u 3 3 u 4 4 5 6 u 5 Normal cell Cancer cell Therefore at age t: Log(I) = (n-1)log(t) + c (where c is a constant) This predicts a straight line relationship between log(i) and log(age) with the slope being one less than the number of steps

60 Stomach cancer incidence by age 50 40 30 20 10 0 27 32 37 42 47 52 57 62 67 72 Age

Stomach cancer: ln(i) by ln(age) 3.8 Total 2.8 1.8 y = 5.0x - 17.8 0.8-0.2 3.2 3.4 3.6 3.8 4.0 4.2 4.4-1.2 Ln(age)

Some limitations of the theory It works well for epithelial tumours, since epithelial cells have continual cell division throughout life It works less well for tissues that have variable rates of division throughout life, e.g. childhood cancers, breast, neural, bone cancers In the case of breast cancer, this is most likely because the theory does not directly allow for cell proliferation (e.g. as happens with breast tissue in puberty) In that situation, a factor can increase the risk of cancer simply by causing partially transformed cells to proliferate (thus making more copies which are susceptible to further changes)

Female breast cancer: ln(i) by ln(age) 7 y = 3.9x - 10.0 6 5 4 3 2 1 3.2 3.4 3.6 3.8 4.0 4.2 4.4

Male breast cancer: ln(i) by ln(age) 2 y = 5.0x - 20.0 1.5 1 0.5 0 3.6 3.7 3.8 3.9 4.0 4.1 4.2 4.3 4.4-0.5-1 -1.5-2

Some testable implications of the theory The model predicts the decline in acceleration at older ages (i.e. that the slope drops below that of a straight line) There are several ways that this can happen, but the most likely one is simply that for older people, they have some cells that have already gone through one or more stages What we see for each person then is a risk which is an average across cells, some of which have less than n stages to go The average slope for a population is then less than n at older ages

Reduced acceleration at older ages: lung cancer incidence 7 6 5 4 3 2 1 3.5 3.7 3.9 4.1 4.3 4.5

Reduced acceleration at older ages: lung cancer acceleration 0.1400 0.1200 0.1000 0.0800 0.0600 0.0400 0.0200 0.0000 3.6 3.7 3.8 3.9 4.0 4.1 4.2 4.3

Some testable implications of the theory If a population is born with one step already accomplished (e.g. if they are born with a genetic susceptibility) then their slope will be 1 less (e.g. if there are 6 steps, and they are born with 1, then they only have 5 steps to go and their slope will be 4)

Age-specific incidence of inherited and sporadic colon cancer. Steven A. Frank PNAS 2005;102:1071-1075 2005 by National Academy of Sciences

Some testable implications of the theory If an exposure (e.g. smoking) acts at two stages, then incidence will be proportional to the square of the daily dose, and the (n-1)th power of the number of years of exposure This is the case for smoking and lung cancer where the incidence is proportional to the square of the daily dose

Some testable implications of the theory Weighting exposure history can help identify likely stage(s) of action

South Carolina Asbestos Textile Worker Study 10 9 8 7 6 5 4 3 2 1 0 <1 1-9.9 10-39.9 40-99.9 100+

Exposure Time Windows ----------------- cumulative exposure ---------------- exposure timewindow person-year at risk

Exposure Time Windows 6 5 4 3 2 1 0 30+ 25-20- 15-10- 5-0-4

Exposure Time Windows 6 5 4 3 2 1 Unadjusted Adjusted 0 30+ 25-20- 15-10- 5-0-4

Models of Carcinogenesis ----------------- cumulative exposure ---------------- --- exposure timewindow person-year at risk

Length of follow-up (f) Starts work (selection out) Age at first exposure (t 0 ) Duration of exposure (d) Age at increment of exposure (t 0 +x) Stops work (selectio n out) Age at end of exposure (t 0 +d) Age at risk (t)

Under These Assumptions, the Excess Risk From Exposure at Age T Is: d E(t) = dose*(t 0 +x) j-1 (f-x) k-j-1 dx 0 t 0 = age at first exposure x = time since first exposure at age t f = length of follow-up at age t d = duration of exposure k = total number of stages j = stage affected

Models of Carcinogenesis: The Armitage-Doll Model We do the analysis six times, each time assuming that asbestos acts solely at one of the six possible stages We then compare the six different models to see which best fits the data

Models of Carcinogenesis: The Armitage-Doll Model Assumed Categorical Continuous stage chi-square RR chi-square 1 19.4 1.3 2.5 2 19.8 1.4 3.7 3 24.9 1.4 5.4 4 24.0 1.4 6.6 5 20.1 1.5 8.8 6 16.1 12.2 8.2

Is ALS a multistep process? Multistage models Identification of stages Multistage model of ALS Implications for future research

What are the steps? Background mutations rates are generally not large enough to explain the population incidence of epithelial tumours However, the population incidence rates are more explainable if some steps involve: Mutation to the DNA repair system Epigenetic and chromosomal changes Physiological changes Clonal expansion Increases in the mutation rate

What are the steps? There are few instances where all or most of the stages have been established. These vary greater between and within cancers, but in general: The early stages often involve somatic mutations or chromosomal aberrations

Example: colorectal cancer Normal epithelium Dysplastic crypt and early carcinoma Intermediate adenoma Late adenoma Carcinoma Metastasis APC/bcatenin K-RAS DCC SMAD4 SMAD2 p53 Other changes 1. Mutation of the APC regulatory pathway (also occurs in small benign tumors) 2. Mutation of a RAS gene 3. Loss of parts of chromosome 18q 4. Loss of functional p53 (loss of protective control over cellular birth and death) [50-85% of colorectal cancer follow this path]

Example: colorectal cancer Inherited MMR mutation MSI by loss of 2 nd MMR allele APC or b- catenin K-RAS TGFb-RII Late stage mutations 1. Inherited mutations in mismatch repair system (MMR) 2. Microsatellite instability 3. Mutation to APC or b-catenin 4. Mutations in K-RAS, TGFb-RII [2-4% of colorectal cancers follow this path]

Is ALS a multistep process? Multistage models Identification of stages Multistage model of ALS Implications for future research

Characteristics of ALS Adult onset condition Even those born with a genetic susceptibility will usually not get the disease till old age, or not at all The same gene mutation can result in different phenotypes (e.g. same mutation can predispose to ALS/FTD/ALS-FTD, but also to schizophrenia, depression and Parkinson's disease) Starts in one region (perhaps with just one cell) and then spreads Once it occurs, then progression is usually relentless Cancer and neurodegeneration are very different phenomena: cancer is an uncontrolled proliferation of cells, whereas neurodegeneration is the result of the death of cells. Nevertheless, they share several key characteristics

Parallels with cancer Multiple hits affect a small group of cells Spread from this small group Relentless progression Anatomy of spread determined by mechanism of spread Metastasis vs invasion

A simple model of ALS risk Birth Onset Death Health E X G T E G Selfperpetuating process Burden of disease causing factors No disease Disease Al-Chalabi and Hardiman, Nature Reviews Neurol 2013

ALS might be a multistep process ALS requires independent steps in order u is a small probability t is age Each step occurs at rate u per year Probability of any step after t years is ut At age t probability that n steps have occurred is (ut) n Last step has probability u Incidence = u(ut) n Ln(incidence) ~ nln(age) Disease requires n+1 steps

SEALS Register Al-Chalabi, Pearce et al. Lancet Neurology 2014; 13: 1108-1113

Netherlands Register Al-Chalabi, Pearce et al. Lancet Neurology 2014; 13: 1108-1113

Piedmont Register Al-Chalabi, Pearce et al. Lancet Neurology 2014; 13: 1108-1113

Irish Register Al-Chalabi, Pearce et al. Lancet Neurology 2014; 13: 1108-1113

Scottish Register Al-Chalabi, Pearce et al. Lancet Neurology 2014; 13: 1108-1113

All age groups (25-74) ALS Register Sex Slope (n) 95% CI Lower limit SEALS (UK) total 4.8 3.9 5.6 male 3.8 2.8 4.8 female 4.9 4.1 5.7 Netherlands total 4.8 4.5 5.2 male 4.4 3.9 4.9 female 5.7 4.9 6.6 Piedmont (Italy) total 4.5 3.8 5.2 male 5.0 4.6 5.5 female 4.3 2.6 6.1 Ireland total 5.6 5.1 6.0 male 5.6 4.8 6.5 female 5.8 5.2 6.5 Total total 4.9 4.6 5.2 male 4.8 4.5 5.2 female 5.2 4.6 5.7 95% CI Upper limit

Ln (Incidence) How many steps to cause ALS? 3 2 1 0-1 y = 4.8x - 18.1 Suggests 6 steps needed 3.0 3.5 4.0 4.5-2 -3 Ln (Age) Adapted from Armitage and Doll, Int J Epidemiol 2004 by Neil Pearce, LSHTM UK

Ln(Incidence) Do we see the same pattern for MS? 4 3.5 3 2.5 2 1.5 1 0.5 0 3.20 3.70 4.20 Ln(Age)

Subgroup analyses Population subgroup analyses are difficult: For certain risk factors (e.g. head injury) we do not have population denominator data and cannot calculate incidence rates for the population subgroups with these characteristics For other factors (e.g. smoking) we can (roughly) estimate population denominators, but we would still not expect to see clear patterns because these are risk factors which may cause a step to occur in some people they are not markers of a step Other factors (e.g. genetic mutations) may directly correspond to a step, and prevalence is (more or less) constant across age-groups, so we can compare incidence rates (using the total population for denominators) between those who have and don t have the factor

Subgroup analyses Case subgroup analyses are more straightforward: All case subgroups have the same (total population) denominators when calculating incidence rates Thus, we can compare the age-specific incidence rates (and slopes) for different types of cases

Conclusions All ALS has a major genetic component Multistep model explains many features of ALS ALS subgroups exist

Is ALS a multistep process? Multistage models Identification of stages Multistage model of ALS Implications for future research

Implications for future research The multistep model is inconsistent with: The hypothesis that the pathological process is present from birth, but that the toxic effect of the disease-causing protein takes time to build up to sufficient levels to trigger disease The hypothesis that ALS involves a dose-dependent, two-step process of genetic risk and subsequent environmental triggers

Multistage model of ALS is consistent Neuronal specificity Vulnerability can be subgroup specific Genetic pleiotropy The gene variant is only one of several steps Spread from a focus Only some neurons will have had all necessary hits Age dependent incidence It takes time to accumulate all hits Genetic and environmental risk Hits in multiple domains Reduced genetic penetrance Individuals not exposed to all steps will remain well with observation

Implications for future research The multistep model is consistent with: The abiotrophy hypothesis which posits that a toxic insult specifically depletes motor neurons: the toxic insult would be one of the steps A recently proposed model of neurodegenerative diseases being the result of somatic mutations. The hypothesis that ALS is the result of long-term aggregation of protein or seeding of prion-like domains in cellular proteins: one of the steps could include protein aggregation in a subset of cells; a further step could include failure to clear the toxic aggregates in a smaller subset; the site of onset can be explained because only some neurons will have undergone all.steps

Implications for future research Individuals with a mutation that accounts for one step might be expected to have a log(age) versus log(incidence) slope of 4 rather than 5 Environmental exposures are probably important for all types of ALS ALS may still be preventable in those with genetic susceptibility Different exposures may cause the same stage to occur Pleiotropy may be important different neurodegenerative diseases may have common causes

Implications for future research Identification of stages Use of multistage model to identify aetiologically distinct subgroups Is ALS the same disease in different parts of the world? Analyses of other neurological conditions

Patients and families

Is ALS a multistep process? Neil Pearce, London School of Hygiene and Tropical Medicine Ammar Al-Chalabi, Institute of Psychiatry, King s College London Zoe Rutter-Locher, King s College London